Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections.
about
Recent Advancements of Treatment for Leptomeningeal CarcinomatosisMultifunctional nanoparticles for brain tumor imaging and therapy.Intrathecal treatment of neoplastic meningitis due to breast cancer with a slow-release formulation of cytarabineActivity of postoperative carboplatin, etoposide, and high-dose methotrexate in pediatric CNS embryonal tumors: results of a phase II study in newly diagnosed children.Biology and treatment of primary central nervous system lymphoma.Treatment options for central nervous system lymphomas in immunocompetent patients.Optimizing antimetabolite-based chemotherapy for the treatment of childhood acute lymphoblastic leukaemia.beta-Endorphin: analgesic and hormonal effects in humans.Contrast-Enhancing Meningeal Lesions Are Associated with Longer Survival in Breast Cancer-Related Leptomeningeal Metastasis.Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections.An intensive multiagent chemotherapy regimen for brain tumours occurring in very young children.Leptomeningeal metastasis: a Response Assessment in Neuro-Oncology critical review of endpoints and response criteria of published randomized clinical trialsIntravitreal chemotherapy for the treatment of recurrent intraocular lymphoma.Neoplastic meningitis resulting from hematological malignancies: pharmacokinetic considerations and maximizing outcomeTreatment of neoplastic meningitis: what is the standard of care?Methotrexate administration directly into the fourth ventricle in children with malignant fourth ventricular brain tumors: a pilot clinical trial.Leptomeningeal metastases: a RANO proposal for response criteria.Leptomeningeal Metastasis: Challenges in Diagnosis and TreatmentCurrent treatment approaches to early childhood medulloblastoma.Gestational trophoblastic disease: does central nervous system chemoprophylaxis have a role?A review of leptomeningeal metastases in pediatrics.The need for prophylactic treatment to the central nervous system in patients with aggressive non-Hodgkin's lymphoma.Prediction of brain delivery of ofloxacin, a new quinolone, in the human from animal data.Ventricular access device placement in the fourth ventricle to treat malignant fourth ventricle brain tumors: technical noteCarcinomatous meningitis: Leptomeningeal metastases in solid tumorsComprehensive craniospinal radiation for controlling central nervous system leukemiaOsmotic blood-brain barrier disruption. Computerized tomographic monitoring of chemotherapeutic agent delivery.Evaluation of osmolality and pH of various concentrations of methotrexate, cytarabine, and thiotepa prepared in normal saline, sterile water for injection, and lactated Ringer's solution for intrathecal administration.Anticancer therapies and CNS relapse: overcoming blood-brain and blood-cerebrospinal fluid barrier impermeability.Complete radiologic response and long-term survival with use of systemic high-dose methotrexate for breast cancer-associated leptomeningeal disease.Treatment approaches for primary CNS lymphomas.Role of intrathecal rituximab and trastuzumab in the management of leptomeningeal carcinomatosis.Chemotherapy in newly diagnosed primary central nervous system lymphoma.Modern concepts in the biology, diagnosis, differential diagnosis and treatment of primary central nervous system lymphoma.Leptomeningeal Carcinomatosis in Esophageal Cancer: Case Report and Review of Literature.Pharmacokinetics and metabolism of methotrexate: an example for the use of clinical pharmacology in pediatric oncology.Rational administration schedule for high-dose methotrexate in patients with primary central nervous system lymphoma.Pathogenesis and management of primary CNS lymphoma.Diagnosis and treatment of primary CNS lymphoma.Bacterial meningitis: new therapeutic approaches.
P2860
Q26798009-CB398711-62AB-4BF4-BF9E-6615B4A62D0CQ26865418-EEE0E747-4C6A-468E-9130-1E1CBBF9CE02Q28346742-CBEC593B-C738-4596-B2B8-4A769CCBB46FQ33344066-B24D7975-C7D3-4662-9657-0A2CA4ECD6CDQ33475480-6DEB58F1-F64B-43A2-9EAF-59615F604D13Q33510785-A669DCA9-098B-40E8-8697-E70B7B0FC833Q33994352-3474B618-9FC5-4FD9-BDEE-AFE8A282BE20Q34039519-8390C780-79E7-4912-BF44-8DBA66B64EEFQ34096206-3F4D0C51-CD47-4F53-9F32-25665E8EF5D0Q34142328-5F090B38-5FA6-4594-B204-C532EDA1DCB8Q34797625-89B21809-7888-4680-B511-EEDD064E8AF1Q35175149-B02824B9-499F-4C64-AF7F-B4741EE2051EQ35309325-E3E3A4D5-9AF8-4CF8-9630-7A7961CA3079Q35799389-3C75DBA3-CD4A-4C34-BC4A-D8DCC68D28E2Q36107024-E3F27755-D884-45CB-B0D7-B0E32708AE35Q36118160-379993CC-FCB4-4EE3-957D-920006F83638Q36236770-CDA7396A-24D1-471D-8BF0-C59DAFB52C50Q36469191-45A29FEA-CB8B-4096-9BC3-05879FA4C011Q36558688-AF086E1F-B424-4500-8257-50CE900A50FAQ36617520-60E643AF-3ECE-447A-BD1F-18F5B225722AQ36690632-0DA3BC9C-B7CC-42CA-982B-D75AD692B2F8Q36704479-D139A6D8-86BB-437C-9631-DCAB7E676112Q36718935-ADAB5DC6-8CA5-4CCD-8253-C7E73A533253Q36762275-41603D0B-77B6-432A-91C8-ACB7654A9AD7Q36851197-E4B5A330-3632-4C75-8B4B-F88612D81DF7Q36905115-8176E8D6-B00C-4F4D-895B-F3936CCAF1C8Q37041124-B6039AE8-D771-4031-9F27-AFADD75407FCQ37261066-75F603FE-E04E-4F33-BD11-5266024E52F7Q37724215-11C2B3E0-33A7-4F00-A040-96E2C3F6D6D7Q37733643-66EC3C6C-CEEA-4DC9-A18C-1AB3DF8E3F1CQ37739428-688C461D-D14B-4A53-8989-24C916A5EF3BQ37784351-D86B5D58-8326-4B4B-A492-B9BD361DDC97Q37905596-D065D8B7-C86C-4F41-B820-64DA8D2AC963Q37911948-0D0CF3A8-4434-4446-A64F-7432F56AF05AQ37950941-1034D7CB-E864-4529-8380-4B48893C9468Q37951561-F194BA66-9710-4A8F-A90B-F3BB93C48510Q38005196-AB4029F2-BC61-4D1B-A691-925D2BD521C2Q38010799-2AFC32BE-85F6-4E6B-A78D-817A69722CAEQ38106613-8DB0D3FC-7C2A-4DB0-B87B-FC20562023CCQ38145360-1BFB7070-6E7F-4F96-8EF7-407E20B5004F
P2860
Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections.
description
1975 nî lūn-bûn
@nan
1975年の論文
@ja
1975年学术文章
@wuu
1975年学术文章
@zh
1975年学术文章
@zh-cn
1975年学术文章
@zh-hans
1975年学术文章
@zh-my
1975年学术文章
@zh-sg
1975年學術文章
@yue
1975年學術文章
@zh-hant
name
Methotrexate: distribution in ...... ricular and lumbar injections.
@en
Methotrexate: distribution in ...... ricular and lumbar injections.
@nl
type
label
Methotrexate: distribution in ...... ricular and lumbar injections.
@en
Methotrexate: distribution in ...... ricular and lumbar injections.
@nl
prefLabel
Methotrexate: distribution in ...... ricular and lumbar injections.
@en
Methotrexate: distribution in ...... ricular and lumbar injections.
@nl
P2093
P1476
Methotrexate: distribution in ...... ricular and lumbar injections.
@en
P2093
P304
P356
10.1056/NEJM197507242930402
P407
P577
1975-07-01T00:00:00Z